Olopatadine/mometasone

Olopatadine/mometasone
Combination of
Olopatadine	Selective histamine H1-receptor antagonist
Mometasone	Topical corticosteroid
Clinical data
Trade names	Ryaltris
Pregnancy; category	AU: B3; ;
Routes of; administration	Nasal spray
ATC code	None;
Legal status
Legal status	AU: S4 (Prescription only) ;

Olopatadine/mometasone, sold under the brand name Ryaltris, is a fixed-dose combination medication for the treatment of allergic rhinitis and rhinoconjunctivitis in adults and adolescents twelve years of age and older.^[1] It contains olopatadine hydrochloride and mometasone furoate monohydrate.^[1] It is sprayed into the nose.^[1]

Common side effects include an unpleasant taste (dysgeusia).^[1]

It was approved for medical use in Australia in December 2019.^[1]^[2]

References[]

^ ^a ^b ^c ^d ^e ^f ^g "Ryaltris (olopatadine hydrochloride and mometasone furoate monohydrate) Nasal Spray". Retrieved 25 July 2020.
^ "Ryaltris nasal spray approved in Australia". OINDPnews. 20 December 2019. Retrieved 25 July 2020.

External links[]

"Olopatadine". Drug Information Portal. U.S. National Library of Medicine.
"Mometasone furoate". Drug Information Portal. U.S. National Library of Medicine.

This drug article relating to the respiratory system is a stub. You can help Wikipedia by .

[Ryaltris_PI-1] ^ ^a ^b ^c ^d ^e ^f ^g "Ryaltris (olopatadine hydrochloride and mometasone furoate monohydrate) Nasal Spray". Retrieved 25 July 2020.

[2] "Ryaltris nasal spray approved in Australia". OINDPnews. 20 December 2019. Retrieved 25 July 2020.

[1]

[2]